SAN ANTONIO — Weight loss via lifestyle intervention showed correlation to improved inflammatory markers in a group of women with HER2-negative breast cancer, according to a presenter here.
Jennifer A. Ligibel, MD, professor of medicine at Dana-Farber Cancer Institute, presented preliminary results of the Breast Cancer Weight Loss (BWEL) trial during a rapid-fire session at the San Antonio Breast Cancer Symposium.
BWEL is a phase 3 randomized study evaluating the impact of a diet- and exercise-based weight-loss intervention on invasive DFS in 3,180 women with stage 2 and 3 HER2-negative